Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
441
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer